Translational Models of Parkinson’s Disease and related Movement Disorders
- 1st Edition - November 28, 2024
- Latest edition
- Editor: Wael Mohamed
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 6 1 2 8 - 5
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 6 1 2 9 - 2
Translational Models of Parkinson’s Disease and Related Movement Disorders focuses on cutting-edge techniques for creating and validating current Parkinson’s Disease translati… Read more
Translational Models of Parkinson’s Disease and Related Movement Disorders focuses on cutting-edge techniques for creating and validating current Parkinson’s Disease translational experimental models. Various characteristics of these models are examined, including the prion-like properties of -synuclein, mitochondrial functions connected to the PINK1-Parkin pathway/CHCHD2, the endolysosome pathway connected to LRRK2, VPS35, and ATP13A2 using cultured cells (including patient iPS cells). This book also highlights the future possibilities of introducing new models for Parkinson’s Disease and related movements disorders, underscoring current advancements, pre-clinical and clinical developments, and future scope related to numerous models.
- Highlights induction and validation of different available experimental models of Parkinson’s Disease
- Provides a comparative prospect of different experimental models of Parkinson’s Disease
- Discusses the advantages and disadvantages of each model, including associated limitations
Student, Researchers and Clinician in Neuroscience, Neurology and Movement disorders
Section I. Understanding PD and related movement disorders
1. Neuroinflammation, glymphatic system, and Parkinson's disease
2. Pharmacotherapy of PD and related movements disorders and their limitations
3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders
4. OMICS and bioinformatics in Parkinson disease and related movements disorders
5. Modeling Parkinson's disease with the alpha-synuclein protein
6. α-Synuclein seeding assay and analysis
Section II. Mammalian models of Parkinson's disease
7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease
8. Stem cell for PD: Technical considerations
9. Deep brain stimulation using animal models of Parkinson's disease
10. The MitoPark mouse model of Parkinson's disease
11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease
Section III. Invertebrate models of Parkinson's disease
12. SCA1 zebrafish model
13. Various zebrafish models of Parkinson's disease: What gives us hope
14. Drosophila PD model
15. Caenorhabditis elegans models of tauopathy
16. LRRK2 in Caenorhabditis elegans model
Section IV. Ethics and regulations related to translational PD models
17. Confounding factors for validation of PD models
18. Neurobehavioral characterization of PD models
19. Ethical regulations for induction and validation of PD models
20. The OMICS and PD models: Hopes or hypes
21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research
1. Neuroinflammation, glymphatic system, and Parkinson's disease
2. Pharmacotherapy of PD and related movements disorders and their limitations
3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders
4. OMICS and bioinformatics in Parkinson disease and related movements disorders
5. Modeling Parkinson's disease with the alpha-synuclein protein
6. α-Synuclein seeding assay and analysis
Section II. Mammalian models of Parkinson's disease
7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease
8. Stem cell for PD: Technical considerations
9. Deep brain stimulation using animal models of Parkinson's disease
10. The MitoPark mouse model of Parkinson's disease
11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease
Section III. Invertebrate models of Parkinson's disease
12. SCA1 zebrafish model
13. Various zebrafish models of Parkinson's disease: What gives us hope
14. Drosophila PD model
15. Caenorhabditis elegans models of tauopathy
16. LRRK2 in Caenorhabditis elegans model
Section IV. Ethics and regulations related to translational PD models
17. Confounding factors for validation of PD models
18. Neurobehavioral characterization of PD models
19. Ethical regulations for induction and validation of PD models
20. The OMICS and PD models: Hopes or hypes
21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research
- Edition: 1
- Latest edition
- Published: November 28, 2024
- Language: English
WM
Wael Mohamed
Dr. Wael Mohamed is Professor of Basic Medical Science at the International Islamic University Malaysia. He obtained his MD and MSc in Clinical Pharmacology from Meoufia Medical School, Egypt, and his PhD in Neuroscience from The Pennsylvania State University. After finishing his neurosurgery training, he began his career as a clinical pharmacologist with psychopharmacology as a subspecialty. Dr. Mohamed specializes in translational brain research and brings more than two decades of experience to the project. His current focal area is the investigation and development of novel treatments for Alzheimer’s Disease and Parkinson’s Disease. He is a member of several key basic and clinical neuroscience societies, including the American Psychological Association, The Society for Neuroscience, National Academy of Neuropsychology, and the International Congress of Neuropsychopharmacology. Dr. Mohamed brings prior book editing experience from Elsevier titles including Pharmacotherapy of Parkinson’s Disease; Essential Guide to Neurodegenerative Disorders; Translational Models of Parkinson’s Disease and related Movement Disorders; and Telehealth in Movement Disorders.
Affiliations and expertise
Basic Medical Science Dept., Kulliyyah of Medicine, International Islamic University Malaysia, Kuantan Campus, Pahang, MalaysiaRead Translational Models of Parkinson’s Disease and related Movement Disorders on ScienceDirect